ARCHIVES

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

This article is from The Cancer Letter archive.

Vol. 23 No. 32 | August 15, 1997

Download PDF Visit The Full Archive

Related Articles

Center And Cooperative Group Clinical Trials Approved By NCI

May 27, 2005

Research Needed On Hormonally Active Agents, Report Finds

August 6, 1999

Collins Sworn In As NIH Director

September 4, 2009

NCI CTEP Approved Trials For the Month of March

March 29, 2013

Study: BRCA2-Negative Women Could Still Have High Risk

December 27, 2013

Foundations Invites Antitobacco Proposals

October 15, 1993